Teschke Rolf
Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt, Germany.
Front Pharmacol. 2019 Jul 23;10:730. doi: 10.3389/fphar.2019.00730. eCollection 2019.
One of the most difficult challenges in clinical hepatology is the diagnosis of a drug-induced liver injury (DILI). The timing of the events, exclusion of alternative causes, and taking into account the clinical context should be systematically assessed and scored in a transparent manner. RUCAM (Roussel Uclaf Causality Assessment Method) is a well-established diagnostic algorithm and scale to assess causality in patients with suspected DILI. First published in 1993 and updated in 2016, RUCAM is now the worldwide most commonly used causality assessment method (CAM) for DILI. The following manuscript highlights the recent implementation of RUCAM around the world, by reviewing the literature for publications that utilized RUCAM, and provides a review of "best practices" for the use of RUCAM in cases of suspected DILI. The worldwide appreciation of RUCAM is substantiated by the current analysis of 46,266 DILI cases, all tested for causality using RUCAM. These cases derived from 31 reports published from 2014 to early 2019. Their first authors came from 10 countries, with China on top, followed by the US, and Germany on the third rank. Importantly, all RUCAM-based DILI reports were published in high profile journals. Many other reports were published earlier from 1993 up to 2013 in support of RUCAM. Although most of the studies were of high quality, the current case analysis revealed shortcomings in few studies, not at the level of RUCAM itself but rather associated with the work of the users. To ensure in future DILI cases a better performance by the users, a list of essential elements is proposed. As an example, all suspected DILI cases should be evaluated 1) by the updated RUCAM to facilitate result comparisons, 2) according to a prospective study protocol to ensure complete data sets, 3) after exclusion of cases with herb induced liver injury (HILI) from a DILI cohort to prevent confounding variables, and 4) according to inclusion of DILI cases with RUCAM-based causality gradings of highly probable or probable, in order to increase the specificity of the results. In conclusion, RUCAM benefits from its high appreciation and performs well provided the users adhere to published recommendations to prevent confounding variability.
临床肝病学中最具挑战性的难题之一是药物性肝损伤(DILI)的诊断。应系统地评估事件发生的时间、排除其他可能原因,并结合临床背景进行透明的评分。RUCAM(罗塞尔·优克福因果关系评估方法)是一种成熟的诊断算法和量表,用于评估疑似DILI患者的因果关系。RUCAM于1993年首次发表,并于2016年更新,目前是全球最常用的DILI因果关系评估方法(CAM)。以下文稿通过回顾使用RUCAM的文献,重点介绍了RUCAM在全球的最新应用情况,并对疑似DILI病例使用RUCAM的“最佳实践”进行了综述。对46266例DILI病例进行的当前分析证实了RUCAM在全球范围内的认可度,所有这些病例均使用RUCAM进行了因果关系检测。这些病例来自2014年至2019年初发表的31份报告。其第一作者来自10个国家,中国位居榜首,其次是美国,德国排名第三。重要的是,所有基于RUCAM的DILI报告均发表在知名期刊上。1993年至2013年期间还发表了许多其他支持RUCAM的报告。虽然大多数研究质量较高,但当前的病例分析显示少数研究存在缺陷,并非RUCAM本身的问题,而是与使用者的工作相关。为确保未来DILI病例中使用者能有更好的表现,提出了一系列基本要素。例如,所有疑似DILI病例应:1)通过更新后的RUCAM进行评估,以方便结果比较;2)根据前瞻性研究方案进行评估,以确保数据集完整;3)从DILI队列中排除药物性肝损伤(HILI)病例,以防止混杂变量;4)纳入基于RUCAM因果关系分级为高度可能或可能的DILI病例,以提高结果的特异性。总之,RUCAM因其高度认可度而受益,只要使用者遵循已发表的建议以防止混杂变量,其表现良好。